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Disrupting thebinding interactionbetweenproprotein
convertase (PCSK9) and the epidermal growth factor-
like domain A (EGF-A domain) in the low-density lipo-
protein receptor (LDL-R) is a promising strategy to
promote LDL-R recycling and thereby lower circu-
lating cholesterol levels. In this study, truncated 26
aminoacidEGF-Aanalogsweredesignedandsynthe-
sized, and their structures were analyzed in solution
and in complex with PCSK9. Themost potent peptide
had an increased binding affinity for PCSK9 (KD =
0.6 mM) compared with wild-type EGF-A (KD =
1.2 mM), and the ability to increase LDL-R recycling
in the presence of PCSK9 in a cell-based assay.
INTRODUCTION
Elevated levels of circulating low-density lipoprotein (LDL) choles-
terol are associated with an increased risk of cardiovascular
disease, the most common cause of premature death in the
United States (Roger et al., 2012) and Europe (Perk et al., 2012).
Cellular uptake and plasma levels of LDL are controlled by the
LDL receptor (LDL-R) through binding of circulating LDL to the
LDL-R at the cell surface, followed by internalization of the com-
plex by clathrin-mediated endocytosis. In the endosomes, low
pH leads to disassociation of the LDL/LDL-R complex, allowing
the receptor to recycle to the cell surface while the LDL is
degraded in the lysosome (Brown and Goldstein, 1986).
The primary regulator of LDL-R levels and thus of circulating
LDL is proprotein convertase subtilisin-like/kexin type 9
(PCSK9) (Abifadel et al., 2003). PCSK9 is a serine protease of
the proprotein convertase family that regulates circulating
LDL-R levels by controlling LDL-R degradation (Horton et al.,
2007; Lambert, 2007). Since the discovery of the first missense284 Chemistry & Biology 21, 284–294, February 20, 2014 ª2014 Elsemutation in PCSK9 and the link to an autosomal-dominant
form of familial hypercholesterolemia (Abifadel et al., 2003),
numerous mutations in the PCSK9 gene have been identified
and associated with hypercholesterolemia (gain of function) or
hypocholesterolemia (loss of function) (Tibolla et al., 2011).
Both PCSK9 and the LDL-R have been well characterized.
PCSK9 is a 70 kDa serine protease that contains three
domains: an N-terminal prodomain, a subtilisin-like catalytic
domain, and a C-terminal cysteine/histidine-rich domain (CTD)
(Figures 1A and 1B; Henrich et al., 2005). PCSK9 undergoes
autocatalytic cleavage, but the 14 kDa prodomain remains non-
covalently attached to the catalytic domain and renders the pro-
tease inactive (Benjannet et al., 2004; Cunningham et al., 2007;
Lagace et al., 2006; Seidah et al., 2003). It is believed that the
prodomain acts as a chaperone and assists in folding of the pro-
tein (Kwon et al., 2008), whereas autocatalytic processing is
crucial for the secretion of PCSK9 (Seidah et al., 2003). The
LDL-R is a multidomain protein that comprises (1) an extracel-
lular domain with an N-terminal ligand-binding domain that
includes seven cysteine-rich repeats (L1–L7), (2) two epidermal
growth factor (EGF) homology domains (EGF-A and EGF-B)
that are separated from a third EGF-like domain (EGF-C) by a
b-propeller domain, and (3) an ‘‘O-linked sugar’’ domain (Lo
Surdo et al., 2011; Figures 1A and 1C).
Functional studies have shown that the plasma levels of LDL-R
are regulated by PCSK9 through inhibition of the recycling of
LDL-R to the surface following internalization, leading todegrada-
tion of the LDL-R in the liver (Maxwell and Breslow, 2004; Park
et al., 2004). The two proteins interact via a 530 A˚2 flat contact
patch between the catalytic domain of PCSK9 and the EGF-A
domain in the LDL-R (Kwon et al., 2008). The interface involves
a central hydrophobic patch with a number of surrounding polar
interactions and putative salt bridges contributing to the high
binding specificity (Figure 1D; Kwon et al., 2008). The size and
shape of the interface suggest that small organicmoleculesmight
not be suitable candidates as PCSK9/LDL-R binding inhibitors. A
number of laboratories have therefore investigated variousvier Ltd All rights reserved
Figure 1. LDL-R and PCSK9 Domain
Structures and Interactions
(A) Model of the interaction between LDL-R and
PCSK9, shown as a ribbon plot with calcium ions
as spheres.
(B) Schematic figure outlining the prodomain,
catalytic domain, and C-terminal domain (CTD)
of PCSK9.
(C) Schematic figure of the LDL-R, highlighting the
seven cysteine-rich repeats, the three EGF-
like domains (EGF-A, EGF-B, and EGF-C), the b
propeller, the sugar-rich domain (SD), and the
transmembrane (TM) domain.
(D) The interface of EGF-A (ribbon plot) and PCSK9
(molecular surface colored according to electro-
static potential; PDB ID: 3BPS). This figure was
inspired by previously published Figures 1 and 2 in
Lo Surdo et al. (2011).
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Truncated EGF-A Peptides Restore LDL-R Recyclingapproaches for inhibiting the PCSK9/LDL-R binding interaction,
including protein domains based on the EGF-A or EGF-AB
domain of the LDL-R (Shan et al., 2008; Zhang et al., 2012), re-
combinant LDL-R fragments (Bottomley et al., 2009; McNutt
et al., 2009; Shan et al., 2008), andmono- or polyclonal antibodies
(Chan et al., 2009; Duff et al., 2009). These approaches have been
evaluated in cell assays or via intravenous injections of mono-
clonal antibodies in mice or nonhuman primates (Chan et al.,
2009). PCSK9 has also been downregulated at the translational
level using small interfering RNA (siRNA) targeting liver PCSK9
(Frank-Kamenetsky et al., 2008), and a recent clinical study
showed that PCSK9 RNAi reduces LDL cholesterol concentra-
tions in humans (Fitzgerald et al., 2013). Thesemethodsall restore
LDL cholesterol uptake, suggesting that PCSK9 is a promising
target for treatment of heart disease (Bottomley et al., 2009).
Peptides are now emerging as therapeutic candidates to
bridge the gap between small-molecule drugs (<500 Da in
mass) and large biologics, including antibodies (>5,000 Da), as
this chemical space is as yet largely unexplored (Craik et al.,
2013). A peptide in this size range would potentially be a suitable
candidate to block the interaction between PCSK9 and the LDL-
R, as it is large enough to fulfill the requirements for a competitive
inhibitor but still small enough to potentially be engineered for
oral bioavailability.
In this study, we investigated the possibility of disrupting the
PCSK9/LDL-R binding interface by using a series of rationally
designed truncated EGF-A analogs. We found that these trun-
cated EGF-A variants could prevent PCSK9-driven LDL-R
degradation in a cell-based assay, and we determined the struc-
ture of a truncated EGF-A analog in solution as well as in com-
plex with PCSK9.
RESULTS
Truncation of the EGF-A C-Terminal Region Has a
Minimal Effect on PCSK9 Binding Affinity
The EGF-A domain contains three disulfide bonds, but their role
in maintaining EGF-A secondary structure has not previouslyChemistry & Biology 21, 284been examined. Systematically removing one disulfide bond at
a time resulted in the peptides EGF-A2 (C297A-C308A),
EGF-A3 (C304A-C317A), and EGF-A4 (C319A-C331A; Figures
2A and 2B). Neither of the disulfide bond analogs (EGF-A2 and
EGF-A3) showed 1D 1H NMR spectra similar to those obtained
from wild-type EGF-A (EGF-A1), and it was concluded that the
missing disulfide bonds were crucial for folding of EGF-A (Fig-
ure S2A available online). However, the 1D 1H NMR spectrum
of the disulfide analog EGF-A4 was similar to that of wild-type
EGF-A (Figure S2A), suggesting that the disulfide bond C319-
C331 is not essential for maintenance of the native fold. Consis-
tent with this hypothesis, EGF-A2 and EGF-A3 showed
nonsaturable binding to PCSK9 in surface plasmon resonance
(SPR) up to 400 mM, whereas the dissociation constant (KD) of
EGF-A4 for PCSK9 (1.18 mM) was similar to that of the wild-
type EGF-A1 (1.01 mM; Table 1; Figure S3) and comparable to
that observed for EGF-A in a previous study (Shan et al., 2008).
Visual inspection of the structure of EGF-A bound to PCSK9
(Protein Data Bank [PDB] ID: 3BPS) indicated that the C-terminal
region (319–334) including disulfide bond C319-C331 was not
involved in complex formation. Consequently, a 26 residue trun-
cated variant of EGF-A that lacked the C-terminal region was
synthesized (EGF-A5; Figures 2A and 2B). This peptide retains
the native connectivity of the other two disulfide bonds and
has a 1D 1H NMR spectrum similar to that of wild-type EGF-A
(Figure S2A). EGF-A5 bound to PCSK9 with a KD comparable
to that observed for the wild-type EGF-A1 or EGF-A4 (Table 1;
Figure S3), which confirms that the C-terminal region does not
play a major role in PCSK9 binding. With the intent of stabilizing
the hairpin loop seen in the EGF-A NMR structure (Figures 3E
and 3F), an alanine residue was introduced in position 292 in
EGF-A5 (EGF-A8) and EGF-A9 (EGF-A10), but this did not
improve the binding to PCSK9 (Table 1).
We also synthesized truncated variants, EGF-A6 and EGF-A7,
in which the disulfide bonds C297-C308 or C304-C317 were re-
placed with C297A-C308A or C304A-C317A, respectively. Like
EGF-A2 and EGF-A3, these peptides did not adopt the native
EGF-A disulfide bond conformation (Figure S2A) and EGF-A6–294, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 285
Figure 2. Sequence Alignment of EGF-A
and Truncated Variants, and Secondary Ha
Chemical Shift of EGF-A5 and Full-Length
EGF-A
(A and B) Ribbon plot of EGF-A1 (A) and sequence
alignment of EGF-A and its analogs (B), showing
the disulfide connectivity and residue numbering.
Cysteine residues are highlighted in dark gray,
mutated residues are in bold, and amidated C
terminus is indicated by *.
(C) Comparison of secondary Ha chemical shifts of
full-length EGF-A and truncated EGF-A5 and
EGF-A9 (Kurniawan et al., 2001), recorded at 298
K in the presence of 5 mM CaCl2.
See also Figure S1 and Table S1.
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produced in yields insufficient to perform SPR.
To evaluate the effect of removing 16 residues and one disul-
fide bond on the stability of the truncated peptides, we carried286 Chemistry & Biology 21, 284–294, February 20, 2014 ª2014 Elsevier Ltd All rights reservout serum stability assays on selected
peptides, including EGF-A1, EGF-A5,
EGF-A6, and EGF-A9. The parent pep-
tide, EGF-A1, showed no proteolytic
breakdown after 24 hr. By contrast, the
truncated EGF-A5 and EGF-A9 under-
went proteolysis of 20.5% and 19.5%,
respectively, after 24 hr. They also
underwent disulfide bond shuffling, as
evidenced by the observation of extra
peaks with the same mass as the native
peptide but different retention times.
The nonactive disulfide bond analog
EGF-A6 was 68.7% intact after 24 hr (Fig-
ures 3 and S4).
Truncated EGF-A5 Has a Fold
Similar to that of Wild-Type EGF-A
To gain insight into the potential structural
changes in EGF-A5 brought about by the
truncation of EGF-A1, we determined the
3D solution structure of EGF-A5. Prelimi-
nary 1D 1H NMR experiments run in 90%
H2O/10% D2O at 298 K gave degenerate
spectra with poor resolution, and no
improvement was observed at lower tem-
peratures (Figure S2B). However, titration
of EGF-A5 with CaCl2 showed that the
peptide required a minimum of 2.5 mM
CaCl2 for stabilization of the structure
(Figure S2C), which was further stabilized
at lower temperature (Figure S2D). For
optimal spectral qualities, all additional
NMR experiments were run in 15 mM
CaCl2 at 283 K. The aH secondary shifts
for EGF-A5 were comparable to those
previously reported for full-length EGF-A
(Figure 2C; Kurniawan et al., 2001), with
some differences noted across residues304–306 in EGF-A (Figure 2C), as expected based on the prox-
imity to the truncated part of the peptide.
We calculated a set of 50 structures using 240 distance
restraints, including 102 sequential, 63 medium-range, 68ed
Table 1. EGF-A Analogs’ Binding Affinity to PCSK9 by SPR
Peptide KD (mM) (SEM) Kon (1/Ms)(10
6) (SEM) Koff (1/s) (SEM) n
EGF-A1 1.01 (0.04) 0.164 (0.008) 0.166 (0.003) 7
EGF-A2 >400 – – 3
EGF-A3 >400 – – 3
EGF-A4 1.18 (0.05) 0.184 (0.009) 0.217 (0.004) 6
EGF-A5 1.17 (0.06) 0.205 (0.013) 0.240 (0.014) 7
EGF-A6 >400 – – 3
EGF-A7a – – – –
EGF-A8 1.27 (0.18) 0.199 (0.020) 0.252 (0.022) 6
EGF-A9 0.56 (0.02) 0.246 (0.008) 0.139 (0.006) 6
EGF-A10 0.59 (0.04) 0.239 (0.007) 0.141 (0.007) 7
See also Figure S3.
aEGF-A7 gave an insufficient yield of correctly folded peptides for anal-
ysis by SPR.
Figure 3. Serum Stability Assay Results
Percentage of peptides EGF-A1, EGF-A5, EGF-A6, and EGF-A9 that remained
in human serum after 24 hr as monitored by RP-HPLC. Error bars denote SEM.
See also Figure S4.
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Truncated EGF-A Peptides Restore LDL-R Recyclinglong-range, and 34 dihedral restraints, with 19 F, 8J, and 7 c1
angles derived from NMR data (Table S2). The 20 lowest-energy
structures (Figures 4A–4D; Table S2) had a global root-mean-
square deviation (rmsd) of 0.51 ± 0.11 A˚ across the Ca atoms
for residues 293–318. Secondary structure analysis revealed
an antiparallel b sheet in the C-terminal region (i.e., strands
V307-L311 and Y315-L318, with a b-turn between the two
strands and two short 3/10-helical turns (E296-C297 and
D299-G303) that correlated well with the aH secondary shifts
(Figure 2C).
Intermediate exchange characteristics were observed in the
spectra of EGF-A5 when the temperature was increased from
288 K to 298 K, most notably in the form of extensive line broad-
ening in the 1D 1H spectra. This broadening presumably arises
from the initiation of unfolding and the formation of a molten
globule, with the possible displacement of Ca2+ ions. This effect
was not observed for full-length EGF-A, which is more con-
strained and stabilized due to the presence of three S-S bonds
(data not shown). As the temperature was further increased to
303–308 K, a major conformation of EGF-A5 could again be
observed with minimal line broadening; however, this conforma-
tion lost its characteristic b-sheet component, as evidenced by
the loss of downfield amide signals and the appearance of
random coil chemical shifts.
Improving the Binding Affinity of EGF-A5
It is well known that H306 in EGF-A is involved in a salt bridge
with D374 in PCSK9 at low pH, with a resulting 50-fold improve-
ment in binding (Bottomley et al., 2009). The gain-of-function
mutation H306Y in EGF-A has been linked to familial hypercho-
lesterolemia (Day et al., 1997; Fouchier et al., 2001) and is also
associated with increased pH-independent binding affinity for
PCSK9 by forming a hydrogen bond with D374 in PCSK9
(Bottomley et al., 2009). We therefore introduced the H306Y
mutation in EGF-A5 to produce EGF-A9. This peptide folded
correctly, as judged by the aH secondary shifts (Figure 2C),
and showed improved binding affinity for PCSK9 (KD =
0.56 mM; Table 1; Figure S3). McNutt et al. (2009) reported that
EGF-AB (H306Y) showed a 2.5-fold increase in binding to
PCSK9 (195 nM) compared with wild-type EGF-AB (500 nM)
at pH 7.4, which is similar to the 2-fold improvement betweenChemistry & Biology 21, 284EGF-A9 and EGF-A5. The decreased KD values observed for
EGF-A9 were due to both increased on-rates (Kon) and
decreased off-rates (Koff) (Table 1).
Truncated EGF-A Variants Inhibit EGF-A and PCSK9
Binding
Fluorescence resonance energy transfer (FRET) binding experi-
ments between biotinylated PCSK9 and V5-EGF-A were carried
out in the presence of various concentrations of EGF-A1, EGF-
A5, EGF-A9, and EGF-A10. The IC50 for EGF-A1 in the FRET
assay was determined to be 2.38 mM. However, although the
shorter analogs EGF-A5, EGF-A9, and EGF-A10 had dissocia-
tion constants comparable to those of EGF-A1, this did not fully
translate to equal inhibition of the PCSK9/EGF-A complex for-
mation, with IC50 values that were 6–8 times less potent than
observed for EGF-A1 (Table 2).
In an attempt to further improve the binding of EGF-A9 to
PCSK9, we designed and synthesized an additional series of
EGF-A analogs (EGF-A11 to EGF-A27), including the most
potent peptide EGF66 from Zhang et al. (2012) (EGF-A23)
and analogs thereof (EGF-A24 to EGF-A27) (Figure 2). Table
S1 provides a detailed rationale for the structure-based, simu-
lation-based, and iterative design process, which included pep-
tide variants designed to test the possibility of removing Ca2+
dependency, introducing an additional stabilizing disulfide
bond, and potentially capitalizing on specific EGF-A binding
interactions identified from modeling studies by introducing
p-stacking, hydrogen bonds, salt bridges, and hydrophobic
interactions with PCSK9 (Table S1). These peptides were suc-
cessfully assembled and characterized by liquid chromatog-
raphy/mass spectrometry (LC/MS; Figure S1). However, none
of the peptides in the series EGF-A11 to EGF-A27 displayed
the correct fold when examined by NMR, as evidenced by
the narrow spectral dispersion of the amide signals (Fig-
ure S2E), and some were produced in insufficient quantities
for activity assays and therefore were not investigated further.
After conducting an extensive series of structure-activity rela-
tionship studies and mutagenesis experiments, we concluded
that EGF-A9 was the smallest and most potent inhibitor, and
that any further shortening of the peptide would lead to
unstructured and nonpotent inhibitors.–294, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 287
Figure 4. 3D NMR Structure of EGF-A5 and EGF-A
(A–D) The 20 lowest-energy NMR structures for EGF-A5 were calculated without calcium (A and B) and with calcium (C and D).
(E and F) The corresponding residues from a previous EGF-A NMR structure (D and E) (Kurniawan et al., 2001) are included for reference. b sheets and a helices
are shown in green and light blue, respectively, and disulfide bonds are highlighted in yellow.
See also Figure S2 and Table S2.
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We measured the ability of the EGF-A analogs to improve recy-
cling of the LDL-R to the cell surface and thereby reduce PCSK9-
mediated degradation of the receptor in an LDL-R functional
assay in the presence of various concentrations of the EGF-A
analogs, using an On-Cell Western assay. EGF-A1, EGF-A5,
EGF-A9, and EGF-A10 were incubated with PCSK9 on Huh7
cells expressing endogenous LDL-R to evaluate disruption of
the LDL-R/PCSK9 interaction and resulting LDL-R recycling.
The EC50 for increasing cell-surface LDL-R in the presence of a
fixed concentration of PCSK9 that reduces surface LDL-R pro-
tein expression by 80% for full-length EGF-A1 was determined
to be 3.44 mM, whereas the shorter analogs EGF-A5, EGF-A9
and EGF-A10 had 5–9 times less potent EC50 activities, consis-
tent with the FRET assay data (Table 2).
EGF-A5 Interacts with PCSK9 Similarly to the Wild-Type
EGF-A
A high-resolution X-ray structure of the EGF-A5/PCSK9 complex
was determined and PCSK9 was found to form an asymmetricTable 2. FRET and LDL-R Functional Assay Results
Peptide FRET IC50 (mM) n LDL-R EC50 (mM) % Response n
EGF-A1 2.38a 27 3.44a 82 39
EGF-A5 15.6 5 28.9 100 3
EGF-A9 14.1 4 16.9 107 4
EGF-A10 18.0 4 25.1 100 3
See also Figure S5.
aAll IC50 values reported are geometric means.
288 Chemistry & Biology 21, 284–294, February 20, 2014 ª2014 Elsecrystallographic dimer in which the second peptide-binding
site of PCSK9 was occluded by crystal contacts (Figures 5A
and 5B). A comparison of the crystal structure with the 20
lowest-energy NMR structures of EGF-A5 showed excellent
alignment between the bound and unbound forms of EGF-A5,
with average Ca rmsds between the NMR structures and the
crystal structure of 0.76 ± 0.11 A˚. The crystal structure also
showed good alignment with the previously published 3D
structure of EGF-AB/PCSK9 (PDB ID: 2W2N) with a heavy
atom backbone rmsd of 0.38 A˚ across corresponding residues.
Molecular Modeling Suggests Similar Interactions for
PCSK9 with EGF-A9 and Full-Length EGF-A(H306Y)
To gain insight into how the truncated EGF-A9 variant might
interact with PCSK9, we performed predictive molecular
modeling using a chimera structure based mainly on PDB ID
3BPS (Kwon et al., 2008) spanning residues 61–657 of PCSK9
(see Experimental Procedures). To confirm the quality of the
model, the average simulation structure of a PCSK9/EGF-A5
complex calculated from ten independent 1 ns trajectories (Fig-
ure 5C) was overlaid with the crystal structure (all Ca rmsds of
1.20 A˚ and 0.75 A˚ for the EGF-A domains). The largest difference
was observed for the N-terminal residue G293, where the
modeled complex showed greater flexibility. The PCSK9/EGF-
A9 complex was modeled in the same way, and the average
simulation structure was overlaid with a PCSK9/EGF-A H306Y
mutant complex (PDB ID: 3GCW) with an rmsd of 1.27 A˚ across
all Ca atoms or 0.53 A˚ for the Ca atoms of the EGF-A domains. As
seen in the PCSK9/EGF-A H306Y mutant structure, the Y306
hydroxyl group in EGF-A9 formed a hydrogen bond withvier Ltd All rights reserved
Figure 5. Structure of EGF-A5/PCSK9 and Proposed Binding of EGF-A9 and the LDL-R to PCSK9
(A) Asymmetric crystallographic dimer of the EGF-A5/PCSK9 complex in ribbon model.
(B) EGF-A5 bound to one molecule of PCSK9, but was occluded from the second by crystal contacts. The crystal structure of EGF-A5/PCSK9 with the bound
ligands is shown in stick model (green, carbon; dark blue, nitrogen; red, oxygen) and the calcium ion is shown as a sphere (gray) on the electrostatic surface of
PCSK9 (red, negative; white, neutral; blue; positive; probe radius 1.4 A˚). EGF-A5 and PCSK9 residues are labeled with the one-letter amino acid code in green and
yellow, respectively. Hydrogen bonds are shown as dotted purple cylinders.
(C and D) Average simulation structures for the complexes of (C) EGF-A5/PCSK9 and (D) EGF-A9/PCSK9.
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for this mutation in the context of the truncated EGF-A scaffold.
DISCUSSION
In this study, we designed, synthesized, and evaluated the
biological activity of rationally minimized peptidic inhibitors of
PCSK9/EGF-A complex formation. To achieve this result, we
identified the smallest part of the EGF-A domain (EGF-A5) that
retained the ability to inhibit PCSK9/LDL-R binding, and showed
that this was a consequence of the minimized EGF-A scaffold
maintaining its native fold in solution and in complex with
PCSK9. We further improved the binding affinity of the truncated
EGF-A scaffold for PCSK9 by introducing a previously reported
gain-of-function mutation (H306Y).Chemistry & Biology 21, 284The finding that the third disulfide bond in EGF-A1 (C319-
C331) could be removed without loss of binding affinity sug-
gested that the C-terminal region was not essential for binding
to PCSK9, and removal of residues 319–334 in EGF-A5 resulted
in a peptide with binding characteristics similar to those of wild-
type EGF-A1. However, the similarity in binding affinity for EGF-
A1 and EGF-A5 did not fully translate into the ability to inhibit
competitive PCSK9/EGF-A binding or PCSK9-driven LDL-R
degradation, as observed by the weaker potency of EGF-A5 in
FRET and LDL-R functional assays. It may be that although the
C-terminal portion of EGF-A plays only a minor role in the contri-
bution to the KD, it hinders access to one or more transition-state
binding sites on PCSK9, either sterically or by presenting a
different electrostatic landscape when bound. Several such
sequential transition-state binding sites have recently been–294, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 289
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this would mean that EGF-A could bind to a transition-state
binding site when EGF-A5 is bound, but not vice versa.
It was previously shown that H306 in EGF-A is involved in a salt
bridge with D374 in PCSK9 at low pH with a resulting improve-
ment in binding affinity (Bottomley et al., 2009), and that the
H306Y substitution in either EGF-A or EGF-AB causes a pH-
independent increase in binding affinity through a hydrogen
bond with D374 in PCSK9 (Bottomley et al., 2009; McNutt
et al., 2009). This could be translated to EGF-A5 with a 2-fold
increase in affinity of EGF-A9 for PCSK9, and molecular-
dynamics analysis suggested that EGF-A9 formed the same
improved interaction with PCSK9 as seen for the full-length
EGF-A (McNutt et al., 2009).
Further attempts to perform structure-activity studies on trun-
cated EGF-A, including removing the Ca2+ dependency by intro-
ducing Lys residues in key positions, extending the N-terminal
region with a Met or an Ala to further stabilize the Ca2+ binding,
and introducing an additional stabilizing disulfide bond stem-
ming from the N-terminal region, proved to be challenging due
to the modest yields obtained during the oxidizing steps. In
cases where the correct product appeared to have been pro-
duced, based on a comparison of high-performance liquid chro-
matography (HPLC) and MS analyses with the correct peptides,
NMR analysis suggested that the peptide did not display the cor-
rect 3D structure, regardless of the NMR conditions used (Fig-
ure S2E). Difficulty in synthesizing the related EGF-A peptides
using solid-phase peptide chemistry was also reported by Zhang
et al. (2012), whose low yields of synthetic material led them to
express the peptides as Fc-fusion proteins. In our study, we
did not attempt to additionally shorten the truncated EGF-A
peptide because results obtained with the disulfide-bond ana-
logs (EGF-A2, EGF-A3, EGF-A6, and EGF-A7) proved that the
first two disulfide bonds in EGF-A are crucial for activity and
structural integrity, and replacing either of themwith Ala residues
results in a peptide with no activity (EGF-A6) or a nonfolded pep-
tide (EGF-A7).
An important aspect of peptide drug development is to deter-
mine the stability of the peptides of interest. One way to do this is
to obtain serum stability measurements to investigate how well
the peptide can survive in a physiological environment. For this
purpose, we chose to use four representative peptides: EGF-
A1 (full-length EGF-A), EGF-A5 (the truncated version), EGF-A9
(the most active truncated peptide), and EGF-A6 (a nonactive
truncated disulfide bond analog). No breakdown of the parent
peptide EGF-A1 was observed after 24 hr, and essentially
100% of the peptide remained. Conversely, some degree of pro-
teolytic degradation occurred for the truncated peptides EGF-A5
(21%), EGF-A6 (22%), and EGF-A9 (20%) after 24 hr. For EGF-
A5 and EGF-A9, a certain degree of disulfide bond shuffling
appeared to occur once the third disulfide bond was removed.
This shuffling was not observed for the disulfide analog EGF-
A6 because it contains only one disulfide bond. These data sug-
gest that the even though the third disulfide bond in EGF-A1 is
not involved in a knotted conformation with the other two disul-
fide bonds (found in the truncated peptides), it appears to have
evolved to ensure that sufficient stabilizing interactions are in
place to provide serum stability. Attempts to further stabilize
the native disulfide connectivity in the truncated peptides by290 Chemistry & Biology 21, 284–294, February 20, 2014 ª2014 Elseconstraining the N or C terminus to the main chain of the peptide
by introducing an additional disulfide bond or lactam bridge did
not result in peptides with the correct fold.
Although EGF-A5 and EGF-A9 showed a similar ability to
inhibit PCSK9/EGF-A complex formation, EGF-A9 had a slightly
greater ability to prevent LDL-R degradation in a cell-based
assay. This could reflect a higher level of binding specificity of
EGF-A9 in a background of numerous other cellular proteins.
In a recent study, Zhang et al. (2012) used phage display to iden-
tify a full-length EGF-A analog (EGF66-Fc) that inhibited the
PCSK9/EGF-A interaction with an IC50 of 1.1 nM. However,
when applied in a cell-based assay to reduce PSCK9 degrada-
tion, the same peptide had a nearly 1,500-fold higher IC50
(1.6 mM). This can be understood in light of the hydrophobic sub-
stitutions in EGF66-Fc, which essentially resulted in a b sheet
without electrostatic selectivity determinants. In comparison,
EGF-A9 required only a 25-fold higher concentration to reach
its EC50 in the cell-based assay, which most likely can be attrib-
uted to the higher level of binding selectivity.
SIGNIFICANCE
To date, the majority of therapeutic strategies to prevent
LDL-R degradation by PCSK9 have focused on the EGF-A
domain of LDL-R. This can be understood from the perspec-
tive that the EGF-A region of LDL-R provides the primary
contact surface with PCSK9 at neutral pH. Current inhibitors
of the interface include anti-PCSK9 antibodies and protein
domains based on the EGF-A or EGF-AB domains of the
LDL-R. However, with advances in the field of solid-phase
peptide synthesis and the ability to make peptides more
‘‘drug like,’’ small peptides are emerging as promising alter-
natives to bridge the gap between larger biologics and small
organic molecules. The truncated EGF-A analogs presented
here are the smallest known peptide-based inhibitors of
PCSK9/LDL-R binding developed using structure-based
rational design. After this manuscript was accepted for pub-
lication, a study using phage display to produce a smaller
inhibitor was reported (Zhang et al., 2013), and the knowl-
edge gained from these complementary approaches should
assist in the development of peptides that promote LDL-R
recycling and thus lower cholesterol levels.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Peptides were assembled on rink-amide resin (0.59 loading; Chem-Impex) at a
0.25 mmol scale using Fmoc solid-phase peptide synthesis on a Symphony
Multiplex Synthesizer. Amino acids (4 eq.) were activated using 4 eq. 2-(6-
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophos-
phate and 8 eq. N,N-diisopropylethylamine in N,N-dimethylformamide (DMF;
2 3 5 min) prior to deprotection of the Fmoc moiety using 30% piperidine in
DMF (2 3 3 min). The following protecting groups were used: Trt or acetami-
domethyl (Acm) (Cys, His, Asn, and Gln), tBu (Asp, Glu, Ser, Thr, and Tyr),
Boc (Lys and Trp), and Pbf (Arg). The peptides were liberated from the resin
by trifluoroacetic acid (TFA):triisopropylsilane:H2O (95:2.5:2.5) over 2 hr before
precipitation with ice-cold diethyl ether and lyophilization.
Peptide Purification and Oxidation
Peptides were purified by HPLC on a Shimadzu Prominence system using a
linear gradient from 0.9% acetonitrile/0.05%TFA to 54% using a Phenomenexvier Ltd All rights reserved
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using a Phenomenex Jupiter 5m (150 3 2) mm column (Figures S1A–S1O).
Peptide masses (Figures S1A–S1O) were determined by electrospray ioniza-
tion MS (Shimadzu Prominence).
Selective removal of the Cys Acm protecting groups and disulfide bond for-
mation was achieved by dissolving 0.5–1 mg/ml peptide in 1 mg/ml iodine and
80% acetic acid. Alternatively, if the reaction proceeded slowly, acetic acid
was substituted formethanol. The reaction wasmonitored byMS as described
above before addition of ascorbic acid until the iodine coloration disappeared.
Serum Stability Assay
Human serum frommale AB plasma (Sigma-Aldrich) was centrifuged at 17,000
g for 10min to remove the lipid content, and the supernatant was incubated for
15 min at 37C prior to the assay. Briefly, a 500 mM stock solution of each pep-
tide was diluted 1:10 in human serum or in PBS as a reference for HPLC elution
times. Triplicate aliquots of 500 ml peptide-serum and peptide-PBS mixtures
were incubated for 0, 1, 4, 8, and 24 hr (peptide-serum) and 0 and 24 hr (pep-
tide-PBS) at 37C. Aliquots of 50 ml were removed at each time point. Serum
proteins were denatured and precipitated by addition of 50 ml 6 M urea
(10 min at 4C) followed by 50 ml of 20% trichloroacetic acid (10 min at 4C)
and centrifugation at 17,000 g for 10 min. Then 40 ml of each resulting super-
natant was analyzed with an ultra-HPLC-MS systemwith a Zorbax 300SB C18
Rapid Resolution HD (2.13 100) mm, 1.8 mmcolumn and gradient elution from
15% acetonitrile/0.05% TFA to 65% acetonitrile/0.05% TFA (0.4 ml/min). Pep-
tide stability was calculated by dividing the area under the HPLC curve
(214 nm) for a sample from a given time point to the equivalent area at time
0 hr (Figures 3 and S4).
NMR Spectroscopy
Truncated and full-length EGF-A analogs (1 mM) were dissolved in a 500 ml
CaCl2 solution of varying concentrations, with the highest Ca
2+ concentration
being 15 mM in 90% H2O/10% D2O (Cambridge Isotope Laboratories). NMR
spectra were recorded on a Bruker Avance 600 MHz NMR spectrometer. 1D
1H spectra were recorded at 283, 288, 293, 298, 303, and 308 K at pH 5.3
(not accounting for deuterium effects) to investigate temperature effects. For
structure determination, a series of 2D data sets, including total correlation
spectroscopy (TOCSY), double quantum filtered correlation spectroscopy
(DQF-COSY), and nuclear Overhauser effect spectroscopy (NOESY) spectra,
were recorded at 283 K (pH 5.3). We used mixing times of 120 ms for the
TOCSY spectra and 100 or 200 ms for the NOESY spectra. The 2D homonu-
clear spectra were generally collected over 4,096 complex data points in the
F2 dimension and 512 increments in the F1 dimension over a spectral width
of 12 ppm. The F2 dimension was zero-filled to 1k data points and both dimen-
sionsweremultiplied by a sine-square function prior to transformation. In addi-
tion, a 2D heteronuclear 1H-13C-HSQC spectrum was recorded at natural
abundance in 100% D2O with 128 increments over a
13C spectral width of
200 ppm. Additional data sets were recorded in 0.5 ml of 50 mM d-Tris,
100 mM NaCl, and 5 mM CaCl2 at 283 K (pH 5.3). All data were processed
using Topspin 2.1 (Bruker) and referenced to the residual solvent signal at
4.94 ppm at 283 K.
NMR Structure Calculations
NMR spectra for EGF-A5 were analyzed and manually assigned in CARA
(Keller, 2004), and used to derive structural information, including interproton
distance restraints and dihedral angle restraints. Interproton distances were
generated from peak intensities in a NOESY spectrum recorded at 283 K
with a mixing time of 200 ms using the program CYANA (Gu¨ntert, 2004). Back-
bone F dihedral angles were generated from coupling constants determined
from the 1D spectrum, with residues having a 3JHaHN < 5 Hz being restrained
to60 ± 30 and residues with a 3JHaHN > 8 Hz restrained to120 ± 30. Anal-
ysis of the Ca and Cb chemical shifts allowed backbone F and J dihedral
angle restraints to be generated through TALOS+ (Shen et al., 2009). Side-
chain c1 angles and stereo-specific assignments of methylene pairs were
generated through analysis of 3JHa-Hb coupling constants derived from an
ECOSY spectra in combination with interproton residue NOE peak intensities
obtained from a 100 ms NOESY spectrum (Wagner et al., 1981). Secondary
structure confirmation was facilitated with a model of the 26-residue EGF-A5
generated from the molecular modeling methods described below.Chemistry & Biology 21, 284Given that all structural restraints were consistent with the crystal structure
of full-length EGF-A, a similar coordination of the Ca2+ ion was assumed and
conservative distance restraints with boundaries of 2.4–3.0 A˚ were included
for the coordinating atoms Thr2 O, Glu4 OE1, Asp18 OD1, Leu19 O, and
Gly22 O. Deuterium-exchange experiments revealed that all amide protons
were exchanged within 5 min; thus, no hydrogen-bond restraints were
included. Initial structures were calculated using a torsion angle simulated an-
nealing protocol within CYANA (Bru¨nger et al., 1998). The final structural family
was generated within CNS (Bru¨nger et al., 1998) using protocols from the
RECOORD database (de Vries et al., 2007), the force field was distributed
with Haddock 2.0 (de Vries et al., 2007; Dominguez et al., 2003), and the cal-
culations included generation of 50 preliminary structures through Cartesian
molecular dynamics and simulated annealing as previously described (Coni-
bear et al., 2012). The final structures were analyzed for stereochemical quality
using MolProbity (Davis et al., 2007), and 20 structures with the lowest energy
and best quality were chosen to represent the solution structure of EGF-A5.
SPR
SPR experiments were performed using a GE Biacore 3000 (GE Healthcare
Lifesciences) with a buffer of 25 mM Tris pH 7.5, 100 mM NaCl, 5 mM
CaCl2, 0.01% Surfactant P20 (GE Healthcare Lifesciences) at a flow rate of
50 ml/min at 25C. Biotinylated wild-type PCSK9 was loaded onto a condi-
tioned streptavidin (SA) Biacore chip at 5 ml/min using a 20 ng/ml protein solu-
tion (1,500–2,000 RU binding). Peptide concentrations were determined by
A280nm measurements using molar extinction coefficients (ExPasy Protparam
tool) and were controlled for peak area equality (A214nm) using reverse-phase
HPLC (RP-HPLC). SPR binding curves were typically generated from five
concentrations (0.1, 0.4, 1.0, 4.0, and 10.0 mM), whereas analogs that showed
minimal PCSK9 binding were assayed up to 400 mM. The Biacore acquisition
cycle involved 30 s of injection, 30 s of dissociation, and at least 60 s of regen-
eration. Data were analyzed using GE BIAevaluation software (version 4.1.1).
Expression and Purification
For expression of biotinylated PCSK9, cDNA corresponding to PCSK9
(UniProtkb/Swiss-Prot Q8NBP7.2) was synthesizedwith a 50 BglII site followed
by nucleotides CCACC and then ATG of methionine 1 to glutamine 692 of
PCSK9, the sequences encoding the FLAG and Avi-tags, double stop codons,
and a 30 XhoI site. This DNA was digested with BglII and XhoI, and subcloned
into pcDNA3.1Zeo (+) vector (Life Technologies) at the BamHI and XhoI sites to
yield the PCSK9 Flag Avi construct. The PCSK9 Flag Avi DNA was used to
transfect HEK293F cells using Freestyle MAX transfection reagent (Life
Technologies) as per the supplied protocol with a 1:1 ratio of plasmid DNA
to Freestyle MAX reagent.
Cells were incubated in 1 l nonbaffled Fernbach flasks with shaking at
90 rpm at 37C and 5% CO2 for 5 days. Then 5 ml of anti-FLAG M2 mAb resin
(Sigma) was added per liter of conditioned media. Batch binding was per-
formed overnight (16C) with gentle mixing. Resin was collected and packed
in a column and washed with 20 column volumes (CV) of 50 mM Tris-Cl, pH
7.5, 300 mM NaCl before elution of bound protein with 0.2 mg/ml FLAG pep-
tide (Sigma). Pooled concentrated fractions were applied to a Superdex-200
(XK16/60) column in the same buffer. Fractions containing PCSK9 were
pooled, flash-frozen in liquid nitrogen, and stored at 80C.
The first EGF-like repeat 1 (EGF-A) from the LDL-R (LDLR NP_000518) was
expressed as follows: A construct was made that consisted of a Honey Bee
Melittin signal peptide (first 21 residues of UniProt accession number
P01501) followed by amino acids DPAM, followed by EGF-like repeat 1 (resi-
dues G314–D354 of UniProt accession number P01130), an SGA linker, a V5
epitope tag, a GG linker, a thrombin cleavage site, and a Fc fragment from
human IgG1 all cloned into the pFastBac1 vector (Life Technologies) at the
50 BamHI and 30 XhoI sites. Viral production and expression were performed
according to the supplied protocol in Sf9 cells, with expression proceeding
for 72 hr from 1 l cultures of Sf9 cells infected with a multiplicity of infection
(moi) of 1.0 at a cell density of 4 3 106 cells/ml.
Conditionedmedia was passed directly over a 5ml Protein A HP column (GE
Healthcare) using an AKTA purifier. The column was washed with 20 CVs of
20 mM sodium phosphate (pH 7.0) and the protein was eluted with 0.1 M citric
acid (pH 3.5) into tubes containing 1M Tris-Cl pH 9.0 (final pH: 7.0–7.4). The Fc
fusion protein was cleaved with bovine alpha-thrombin (Haematologic–294, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 291
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contained the EGF-A V5 fragment (0.9 mg of EGF-A V5/L media) and was
stored at 80C.
FRET Binding Assay
Peptide 503 stock solutions in DMSO were aliquoted into a 384-well white
microtiter plate and incubated with 150 nM biotinylated PCSK9 in binding
buffer (50 mM sodium phosphate pH 7.4, 150 mM NaCl, 0.5 mM CaCl2,
0.1% BSA, and 0.01% Tween-20) for 15 min at room temperature before
EGF-A V5 (150 nM) was added and incubated for 60 min. Nonspecific binding
was assessed with 94 mM untagged EGF-A peptide. PCSK9/EGF-A binding
was monitored with the addition of 20 ng/ml of anti-V5 antibody labeled with
Europium (FRET donor; CisBio) and 80 nM SA-labeled XL665 (FRET acceptor;
CisBio) diluted in binding buffer containing 200 mM KF (Sigma-Aldrich) and
incubated for 5 hr. Close proximity of the FRET pair was read on an Envision
2103 (Perkin Elmer) with excitation at 337 nm and emissions at 615 nm (donor)
and 665 nm (acceptor). The measurements were normalized by ratiometric
analysis of the acceptor to donor emissions.
LDL-R Functional Assay
Huh7 cells were obtained from the Japanese Collection of the Research
Bioresources Cell Bank and maintained in high-glucose Dulbecco’s modified
Eagle’s medium (Life Technologies) supplemented with 10% fetal bovine
serum, 10 mM HEPES, 2 mM L-Glut, and 1% Penn/Strep. LDL-R protein
expression following treatment with EGF-A analogs was determined in the
presence of IC80 concentrations of PCSK9 utilizing an On-Cell Western
assay (LI-COR Biosciences). Briefly, cells were grown to approximately
90% confluency in Collagen I 384-well microtiter plates (BD Biosciences)
and starved for 1 hr in 4% lipoprotein-deficient serum media. EGF-A analog
screening was performed in an 11-point, 0.5 log dilution format with a top
concentration of 100 mM. Compounds of interest were added to the plate
together with a fixed 10 mg/ml concentration of PCSK9 corresponding to
the level of PCSK9 required to decrease LDL-R in Huh7 cells by 80%.
This IC80 level of PCSK9 defined the zero percent effect (ZPE). The high
percent effect (HPE) was defined by saturating concentrations of wild-type
EGF-A in the presence of the IC80 level of PCSK9. Cells were incubated in
the mixture of EGF-A analog and PCSK9 for 5 hr, and following treatment,
the medium was removed and the cells were fixed in a 10% formalin solution
(Sigma). The formalin was then discarded and the cells were washed with
0.1% Tween in PBS at room temperature. Odyssey blocking buffer (LI-
COR Biosciences) was then added and the cells were incubated at room
temperature with gentle rocking for 1 hr. Blocking buffer was removed and
replaced with a 1:300 dilution of primary goat anti-human LDL-R antibody
(R&D Systems) prepared in Odyssey blocking buffer, and plates were incu-
bated overnight at 4C.
The following day, the primary antibody solution was removed and
the plates were washed with 0.1% Tween in PBS at room temperature. The
cells were then treated with a second antibody solution containing a 1:2,000
dilution of IRDye800CW (LI-COR Biosciences) and 1:5,000 of TO-PRO-3
(Life Sciences) prepared in Odyssey buffer and incubated for 1 hr (room tem-
perature). The plates were again washed with 0.1% Tween in PBS at room
temperature and then imaged simultaneously at 700 and 800 nm with an
Odyssey Infrared Imager (LI-COR Biosciences). Signal output was normalized
by ratiometric analysis of the 700 nm values applied to the 800 nm readings. To
determine the compound EC50, the data for HPE and ZPE control wells were
first analyzed and the mean, SD, and Z prime were calculated for each plate.
Values for the EGF-A analogs were converted into percent effect using the ZPE
and HPE controls as 0% and 100% activity, respectively. The following equa-
tion was applied to convert each well reading into percent effect:
% effect= 100 100  ððsample  HPEÞ=ðZPE HPEÞÞ:
X-Ray Crystallography
Purified PCSK9 was concentrated to 8.7 mg/ml in a buffer containing 50 mM
Tris, 0.3 M NaCl, 0.5 mM CaCl2, pH 7.5, before adding a 5:1 molar excess
EGF-A5. The mixture was loaded onto a Superdex 200 GL 10/300 and the
two components comigrated in a single peak as observed by LC/MS. The
PCSK9-EGF-A5 complex was concentrated to 5.5 mg/ml using a centrifugal292 Chemistry & Biology 21, 284–294, February 20, 2014 ª2014 Elseconcentrator (Amicon Ultra 3 kDa). Commercially available screens were set
up using drops formed from 100 nl complex plus 100 nl reagent, equilibrating
by vapor diffusion over 65 ml of well solution in sitting drop plates at 22C
and 4C.
Crystals were grown over 4 M ammonium acetate, pH 7 or 8.5, at 4C. They
were then transferred to a cryoprotectant-containing reservoir solution plus
25% glycerol (v/v), 1 mM CaCl2, and 0.1 mM EGF-A5, and flash-cooled in
liquid nitrogen for data collection at IMCA-CAT at the Advanced Photon
Source. Crystals that diffracted to 2.6 A˚ belonged to the space group
P212121 with unit cell dimensions of a = 126.4 A˚, b = 131.4 A˚, c = 134.6 A˚,
and a = b = g = 90, and contained one PCSK9/EGF-A5 complex and one
unbound PCSK9molecule. The structure was solved bymolecule replacement
using Phaser (McCoy et al., 2007), and model building and refinement were
done with the softwares Coot (Emsley and Cowtan, 2004) and Buster (Smart
et al., 2012), respectively.
Molecular Modeling
Since no complete PCSK9/EGF-A crystal structure was available, chimera
structures based on several PDB files were prepared, with all overlays per-
formed in SPDBV v4.01 (Guex and Peitsch, 1997). The EGF-A domain and
the catalytic domain of PCSK9 were taken from PDB ID 3BPS (Kwon et al.,
2008). The C-terminal domain of PCSK9 (residues 453–657) was taken from
PDB ID 3P5C (Bottomley et al., 2009), and an absent loop in the catalytic
domain (residues 212–219) was inserted from PDB ID 3H42 (Chan et al.,
2009). Shorter loopsweremanually inserted into the catalytic domain (residues
173–176 and 212–219) and C-terminal domain (residues 572–576 and 660–
670) before the introduced residues were energy minimized using YASARA
dynamics (Krieger et al., 2002) and the NOVA force field.
The systems were solvated with TIP3P water and neutralized by Na+/Cl
counterions to a final concentration of 100 mM in VMD1.9.1. (Humphrey
et al., 1996). This generated systems of approximately 62,000 atoms, including
17,500 water molecules. Each protein complex was equilibrated using a step-
wise relaxation procedure over 2.5 ns before ten independent production runs
of 1 nswere carried out for each system using ACEMD (Harvey et al., 2009) and
CHARMM27 force-field parameters (NVT with a 2 fs integration time step) as
previously described (Swedberg et al., 2011). Coordinates were saved every
100 simulation steps, producing the 50,000 frames per ten simulation trajec-
tories used for analysis in VMD.
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